Crossmark

Posterior cortical atrophy: reorganization of the dorsal attention network and its implications on volume loss and clinical performance

Crossref DOI link: https://doi.org/10.1007/s00415-025-13466-6

Published Online: 2025-10-22

Published Print: 2025-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Singh-Reilly, Neha https://orcid.org/0000-0002-3614-9179
Graff-Radford, Jonathan

Machulda, Mary M.

Schwarz, Christopher G.

Knopman, David S.

Petersen, Ronald C.

Jack, Clifford R. Jr.

Lowe, Val J.

Josephs, Keith A. https://orcid.org/0000-0003-2930-8634
Whitwell, Jennifer L. https://orcid.org/0000-0001-6914-1563
Funding

Funding for this research was provided by:

National Institutes of Health (R01-AG50603, U01-AG006786)

Alzheimer's Association (NIRG-12-242215)
License Information

Text and Data Mining valid from 2025-10-22

Version of Record valid from 2025-10-22
More Information

Article History

Received: 23 July 2025

Revised: 2 October 2025

Accepted: 11 October 2025

First Online: 22 October 2025

Declarations

:

: Drs. Singh-Reilly, Whitwell, Machulda, Schwarz, and Josephs reported receiving research funding from the NIH. Dr. Graff-Radford serves on the DSMB for NINDS stroke NET and is an investigator for trials sponsored by EISAI and Cognition Therapeutics. He is an associate editor for JAMA Neurology. Dr. Jack receives no personal compensation from any commercial entity and has no conflicts. He receives research support from NIH, the GHR Foundation, and the Alexander Family Alzheimer’s Disease Research Professorship of the Mayo Clinic. Dr. Lowe reported consulting for Bayer Schering Pharma, Piramal Life Sciences, Life Molecular Imaging, Eisai Inc., AVID Radiopharmaceuticals, and Merck Research and receiving research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, Eli Lilly and Company, and the NIH (NIA, NCI). Dr. Peterson reported serving on scientific advisory boards for Elan Pharmaceuticals and GE Healthcare; he receives royalties from publishing mild cognitive impairment (Oxford University Press, 2003) and receives research support from NIH. Dr. Knopman reported serving on the DSMB of the DIAN-TU study; he is a site PI for clinical trials sponsored by Biogen, Lilly, and the University of Southern California and is funded by NIH.

: The study was approved by the Mayo Clinic IRB.

: Informed consent was obtained from all patients to participate in this study.

Document is current

Any future updates will be listed below